News

Neurons duped into delivering mitochondria to cancer cells found fueling tumor spread
University of South Alabama researchers report that neurons can transfer mitochondria directly to cancer cells, enhancing ...
Targeted Oncology1d
FDA Approves Updated Labels on CAR T-Cell Therapies, Eliminating REMS
FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.
A cure for type 1 diabetes? Beta cell replacement with zimislecel achieves insulin independence in early trial
In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...
Hosted on MSN1mon
Blue Label considers listing Cell C on JSE - MSN
Blue Label has a non-controlling 49.5% stake in Cell C, and is looking to get an additional 4.04% stake via The Prepaid Company (TPC) in order to get control of South Africa’s fourth-biggest ...
Science Daily1mon
New molecular label could lead to simpler, faster tuberculosis tests
Chemists found a way to identify a complex sugar molecule in the cell walls of Mycobacterium tuberculosis, ... New molecular label could lead to simpler, faster tuberculosis tests Date: May 5, 2025 ...
ascopubs.org2mon
Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation: An Open-Label, Multicenter ...
The aim of this open-label, multicenter, randomized controlled trial was to determine the efficacy and safety of sequential umbilical cord–derived mesenchymal stem cell (UC-MSC) infusion for ...
Tech Financials on MSN4mon
Is Blue Label Financing Cell C Through Airtime Purchases? - MSN
On January 24, 2025, Blue Label announced that ICASA had approved the transfer of Cell C’s spectrum and network licenses, ...
Nanowerk5mon
AI advances label-free photoacoustic microscopy for confocal cell imaging
Jan 19, 2025: AI advances label-free photoacoustic microscopy for confocal cell imaging (Nanowerk News) A research team at POSTECH has developed a technology that surpasses the constraints of ...
ascopubs.org1y
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma ...
Background: Autologous (auto) CD19-directed CAR T-cell therapy can induce long-term remissions for pts with R/R LBCL but approximately 60% will experience disease progression resulting in poor ...
The New York Times1y
First Patient Begins Newly Approved Sickle Cell Gene Therapy
On Wednesday, Kendric Cromer, a 12-year-old boy from a suburb of Washington, became the first person in the world with sickle cell disease to begin a commercially approved gene therapy that may ...
FiercePharma1y
AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansion - Fierce Pharma
Less than a year ago, AbbVie's star immunology drug Rinvoq picked up its seventh FDA approval< | AbbVie's Rinvoq has racked up seven FDA approvals in recent years, and another expansion into giant ...
BioSpace1y
Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion - BioSpace
Roche ‘s Genentech subsidiary on Monday announced that its bispecific T-cell engager Columvi (glofitamab) improved survival in a Phase III lymphoma trial, with the company planning to seek a full, ...